This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Two-Year Data Show Long-Term Benefits Of Chronic Soliris® Therapy In Patients With AHUS

Soliris was well tolerated in the study. The most common drug-related AEs were headache, leukopenia, lymphopenia, and cough/productive cough. 2

Efficacy of Soliris Regardless of Identified Genetic Mutation

In a poster session on November 1, researchers presented an analysis of efficacy parameters across three Soliris studies (two prospective and one retrospective) based on the presence or absence of genetic abnormalities. 3 An estimated 50-70% of patients with aHUS have identifiable genetic mutations or complement factor H (CFH) auto-antibodies that cause chronic, uncontrolled, and excessive activation of the complement system. 4,5 The risk of death or end-stage renal disease (ESRD) is similar in patients both with and without an identified mutation. 5,6

Across the three Soliris studies, the efficacy of Soliris – as measured by TMA event-free status, platelet normalization, hematological normalization, and improvement in measures of renal function – was similar in patients regardless of the presence or absence of an identified genetic abnormality. 3

“In three separate clinical studies, aHUS patients with and without identified genetic mutations or CFH auto-antibodies demonstrated similar improvements in clinical outcomes, including reduced disease burden, reduced complement-mediated TMA, improved renal function, and reduced need for supportive care intervention,” said Timothy Goodship, M.D., Professor of Renal Medicine at Newcastle University and the lead author of the poster. “Given the risk of life-threatening systemic TMA events and organ damage in these patients, and the greater clinical improvements associated with early treatment, Soliris therapy can be started immediately at the time of diagnosis, without the delay of waiting for genetic testing, which can take several months to complete.”

About aHUS

aHUS is a chronic, ultra-rare, and life-threatening disease in which a genetic deficiency in one or more complement regulatory genes causes chronic uncontrolled complement activation, resulting in complement-mediated thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body. 7,8 Permanent, uncontrolled complement activation in aHUS causes a life-long risk for TMA, which leads to sudden, catastrophic, and life-threatening damage to the kidney, brain, heart, and other vital organs, and premature death. 7,9 Sixty-five percent of all patients with aHUS die, require kidney dialysis, or have permanent kidney damage within the first year after diagnosis despite plasma exchange or plasma infusion (PE/PI). 6,10 The majority of patients with aHUS who receive a kidney transplant commonly experience subsequent systemic TMA, resulting in a 90% transplant failure rate in these TMA patients. 11

aHUS affects both children and adults. 5 Complement-mediated TMA also causes reduction in platelet count (thrombocytopenia) and red blood cell destruction (hemolysis). While mutations have been identified in at least ten different complement regulatory genes, mutations are not identified in 30-50% of patients with a confirmed diagnosis of aHUS. 5

About Soliris

Soliris is a first-in-class terminal complement inhibitor developed from the laboratory through regulatory approval and commercialization by Alexion. Soliris is approved in the US, European Union, Japan and other countries as the first and only treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, chronic, ultra-rare, and life-threatening blood disorder, characterized by complement-mediated hemolysis (destruction of red blood cells). Soliris is indicated to reduce hemolysis.

4 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs